Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GRIN2C | Q14957 | 6/20 | 0.44 |
| ▸ | MTNR1B | P49286 | 1/20 | 0.43 |
| ▸ | LMNA | P02545 | 1/20 | 0.41 |
| ▸ | TP53 | P04637 | 1/20 | 0.40 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.40 |
| ▸ | FKBP1A | P62942 | 3/20 | 0.39 |
| ▸ | MEN1 | O00255 | 2/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13809251 | 0.90 | GRIN2C (0.49) | GRIN2CMTNR1BLMNAFKBP1AMEN1 | |
| SCHEMBL13809245 | 0.82 | RXFP1 (0.45) | GRIN2CMTNR1BLMNATP53RXFP1 | |
| SCHEMBL13809247 | 0.82 | GRIN2C (0.49) | GRIN2CLMNATP53MEN1KMT2A | |
| SCHEMBL13809246 | 0.80 | GRIN2C (0.51) | GRIN2CLMNATP53MEN1KMT2A | |
| SCHEMBL13809227 | 0.75 | GRIN2C (0.43) | GRIN2CMTNR1BLMNATP53MEN1 | |
| SCHEMBL13809233 | 0.75 | GRIN2C (0.43) | GRIN2CMTNR1BLMNAMEN1KMT2A | |
| SCHEMBL13809007 | 0.74 | GRIN2C (0.43) | GRIN2CLMNAMEN1KMT2A | |
| SCHEMBL13809240 | 0.73 | GRIN2C (0.54) | GRIN2CMTNR1BFKBP1AMEN1KMT2A | |
| SCHEMBL4416128 | 0.72 | TRPV1 (0.46) | GRIN2CMTNR1BTP53RXFP1FKBP1A | |
| SCHEMBL10025907 | 0.70 | OPRD1 (0.38) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2009073545-A2 | TETRAHYDRO-ISOQUINOLINE PPAT INHIBITORS AS ANTIBACTERIAL AGENTS | MAXTHERA, INC. (US) | 2009-06-11 | — | — | WO | disclosed |